Merck Serono Says Partnering Part Of Its Future, Seeks Anti-PD-L1 Deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.